Stockscreener 앱 받기
35.90
1.21%
0.3825
전일 마감가:
$35.52
열려 있는:
$36.6
하루 거래량:
263.90K
Relative Volume:
0.24
시가총액:
$4.07B
수익:
$14.09M
순이익/손실:
$-176.94M
주가수익비율:
-16.70
EPS:
-2.15
순현금흐름:
$-141.24M
1주 성능:
-13.27%
1개월 성능:
-1.59%
6개월 성능:
+85.41%
1년 성능:
+96.77%
1일 변동 폭
$34.99
$36.60
1주일 범위
$34.52
$41.80
52주 변동 폭
$14.06
$42.00
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
명칭
Newamsterdam Pharma Company Nv
전화
35 206 2971
주소
GOOIMEER 2-35, NARRDEN
NAMS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
35.92 | 4.03B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.16 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
728.77 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
475.25 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
926.87 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
208.37 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 재개 | H.C. Wainwright | Buy |
| 2025-08-25 | 개시 | Wells Fargo | Overweight |
| 2025-07-17 | 개시 | Goldman | Neutral |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2025-06-10 | 개시 | Stifel | Buy |
| 2025-06-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-05-15 | 개시 | TD Cowen | Buy |
| 2024-03-14 | 개시 | Scotiabank | Sector Outperform |
| 2024-01-18 | 개시 | Guggenheim | Buy |
| 2024-01-16 | 개시 | Piper Sandler | Overweight |
| 2023-10-30 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Newamsterdam Pharma Company Nv 주식(NAMS)의 최신 뉴스
NAMS: PREVAIL CVOT remains on track for 2026, with regulatory and commercial momentum building - TradingView
Is NewAmsterdam Pharma Company N.V. (KH6) stock attractive post correction2025 Stock Rankings & Real-Time Chart Breakout Alerts - Newser
How NewAmsterdam Pharma Company N.V. (KH6) stock trades after earningsWeekly Trade Analysis & Consistent Profit Trade Alerts - Newser
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock gain from lower inflationAnalyst Upgrade & Weekly High Conviction Ideas - Newser
Transcript : NewAmsterdam Pharma Company N.V. Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 03 - MarketScreener
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock see PE expansion2025 Momentum Check & Fast Moving Stock Trade Plans - Newser
Is NewAmsterdam Pharma Company N.V. (KH6) stock a defensive play amid uncertaintyEarnings Summary Report & Reliable Intraday Trade Alerts - Newser
Will NewAmsterdam Pharma Company N.V. stock benefit from commodity pricesGap Down & Smart Money Movement Alerts - Newser
Will NewAmsterdam Pharma Company N.V. (KH6) stock announce special dividendWeekly Earnings Recap & Technical Entry and Exit Alerts - Newser
Is NewAmsterdam Pharma Company N.V. Equity Warrant stock a dividend growth opportunity2025 Risk Factors & AI Forecasted Entry and Exit Points - Newser
Why NewAmsterdam Pharma Company N.V. (KH6) stock signals breakout potential2025 Stock Rankings & Low Drawdown Momentum Ideas - Newser
(NAMS) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Can NewAmsterdam Pharma Company N.V. Equity Warrant stock outperform in 2025 bull marketPortfolio Gains Report & Technical Buy Zone Confirmation - BỘ NỘI VỤ
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December - Sahm
NewAmsterdam Pharma stock hits all-time high at 41.56 USD - Investing.com India
NewAmsterdam Pharma stock hits all-time high at 41.56 USD By Investing.com - Investing.com Australia
NewAmsterdam (Nasdaq: NAMS) to host investor fireside chats at Evercore, Citi, Piper - Stock Titan
Discipline and Rules-Based Execution in NAMSW Response - news.stocktradersdaily.com
What drives NewAmsterdam Pharma Company NV KH6 stock priceDebt-to-Equity Ratio Analysis & Get Ahead with Our Profit-Packed Picks - earlytimes.in
Is NewAmsterdam Pharma Company N.V. Equity Warrant stock a top pick in earnings seasonSwing Trade & Safe Investment Capital Preservation Plans - newser.com
Can a trend reversal in NewAmsterdam Pharma Company N.V. Equity Warrant lead to recovery - newser.com
Technical analysis overview for NewAmsterdam Pharma Company N.V. Equity Warrant stockMarket Movers & Risk Controlled Stock Alerts - newser.com
Is NewAmsterdam Pharma Company N.V. stock a good choice for value investorsQuarterly Risk Review & Weekly Market Pulse Alerts - newser.com
Will NewAmsterdam Pharma Company N.V. stock maintain dividend yield - newser.com
Is NewAmsterdam Pharma Company N.V. (KH6) stock a fit for income portfoliosOil Prices & Long-Term Growth Stock Strategies - newser.com
How NewAmsterdam Pharma Company N.V. stock performs in high volatility marketsPortfolio Gains Report & Safe Entry Zone Identification - newser.com
What does recent volatility data suggest for NewAmsterdam Pharma Company N.V. Equity WarrantPortfolio Growth Summary & Technical Buy Zone Confirmation - newser.com
How NewAmsterdam Pharma Company N.V. (KH6) stock compares with tech leaders2025 Momentum Check & Risk Adjusted Swing Trade Ideas - newser.com
Visual analytics tools that track NewAmsterdam Pharma Company N.V. Equity Warrant performanceIndex Update & Weekly High Momentum Picks - newser.com
How NewAmsterdam Pharma Company N.V. Equity Warrant stock performs in stagflation2025 Biggest Moves & AI Forecast for Swing Trade Picks - newser.com
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock recover faster than marketJuly 2025 Patterns & Weekly Top Gainers Trade List - newser.com
(NAMS) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Can NewAmsterdam Pharma Company N.V. Equity Warrant stock withstand economic slowdownJuly 2025 Action & Precise Swing Trade Entry Alerts - newser.com
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock maintain momentum in 2025 - newser.com
Published on: 2025-11-16 17:37:14 - newser.com
Advanced analytics toolkit walkthrough for NewAmsterdam Pharma Company N.V. Equity WarrantMarket Volume Report & Low Drawdown Momentum Trade Ideas - newser.com
NewAmsterdam: Obicetrapib MAA Filings Merit Continued 'Buy' Rating (NASDAQ:NAMS) - Seeking Alpha
Why NewAmsterdam Pharma Company N.V. stock is seen as undervaluedDollar Strength & AI Based Buy and Sell Signals - newser.com
Can NewAmsterdam Pharma Company N.V. (KH6) stock surprise markets with earningsPortfolio Risk Summary & Long-Term Safe Investment Plans - newser.com
Using data models to predict NewAmsterdam Pharma Company N.V. Equity Warrant stock movement2025 Technical Overview & Accurate Intraday Trade Tips - newser.com
Tools to assess NewAmsterdam Pharma Company N.V.’s risk profile2025 Dividend Review & Technical Confirmation Trade Alerts - newser.com
Is NewAmsterdam Pharma Company N.V. Equity Warrant stock trading at a premium valuationJuly 2025 Recap & Technical Pattern Based Buy Signals - newser.com
Newamsterdam Pharma Company Nv (NAMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.29%
1.26%
자본화:
|
볼륨(24시간):